MindBio Therapeutics Closes Oversubscribed Private Placement

Vancouver, British Columbia — April 1, 2026 — Leads & Copy — MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF) has closed an upsized non-brokered private placement for gross proceeds of $1,437,828.87.

The biotechnology company, which focuses on commercializing prediction technologies for drug and alcohol intoxication detection using speech analytics and artificial intelligence, issued 2,396,381 units at a price of $0.60 per unit.

Each unit consists of one common share of the company and one share purchase warrant. Each warrant allows the holder to acquire an additional share at $0.80 for thirty-six months following the closing of the offering, subject to accelerated expiry if the closing price of shares on the Canadian Securities Exchange exceeds $1.00 for ten consecutive trading days.

The company intends to use the net proceeds to accelerate the development and deployment of proprietary hardware and edge technology. This technology will enable the remote and scalable use of MindBio’s intoxication detection solution at mining sites, for recruitment of specialized personnel, and for general working capital purposes.

MindBio also announced agreements with two arm’s length service providers for promotional, communications, marketing, and advertising services. Stockouse Publishing Ltd dba The Market Link was engaged pursuant to an advertising campaign agreement, and Investor Brand Network (IBN) was engaged pursuant to a syndicated communications agreement. The purpose of these engagements is to increase public awareness and broaden dissemination of news and information. Neither engagement includes market-making services, and no securities of the company will be issued as compensation.

The Market Link engagement began on March 24, 2026, and will continue until March 24, 2027. Services include access to issuer advertising inventory across listed platforms, strategic support from an account manager, campaign execution, and performance reporting. The Market Link will receive cash compensation of $36,750 payable upfront upon closing of the private placement.

The IBN engagement commenced on March 25, 2026, and will continue until March 25, 2027. IBN will provide an investor awareness and media exposure program. Services include ongoing content distribution, such as articles, newsletter features, press release amplification, and recap coverage across IBN’s media, syndication, and social channels. The engagement also includes promotional support through interviews, social media relations, and access to IBN’s partner network and consulting experience. IBN will receive cash compensation of $34,847.50 per quarter for a 12-month term, for aggregate compensation of $139,390.

In connection with the completion of the offering, the Company paid aggregate cash fees of $70,183.97 and issued an aggregate of 116,973 non-transferable Share purchase warrants to eligible third-parties who introduced subscribers to the Offering. Each Finder Warrant entitles the holder thereof to acquire one Share at a price of $0.80 for a period of thirty-six months after the date of issue, subject to accelerated expiry in the event the closing price of the Shares on the CSE exceeds $1.00 for ten consecutive trading days.

All securities issued in connection with the offering are subject to restrictions on resale for a period of four months and one day, in accordance with applicable securities laws. The offering remains subject to final regulatory approvals.

MindBio is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with accuracy by using the human voice. The Company is now collecting data that will allow its prediction tool to work on other types of intoxication for use in consumer and enterprise environments.

Source: MindBio Therapeutics Corp.